|View printer-friendly version|
BeyondSpring Advancing Patient Targeting Strategies for Lead Asset Plinabulin
In this study,
“There is an enormous need to predict, with confidence, an individual cancer patient’s likelihood of response to therapies being considered,” said Dr.
“Plinabulin is already in global Phase 3 trials for NSCLC, and this new discovery opens up the potential of developing multiple indications for Plinabulin using this biomarker-based approach to patient selection for increased efficacy. Gene expression profiles at baseline that are predictive of outcomes are achievable and will allow
The AACR Annual Meeting will take place from
Cautionary Note Regarding Forward-Looking Statements